BackLAVA Therapeutics NV Overview

LAVA Therapeutics NV Total Current Liabilities

Latest total current liabilities for LVTX: $4.2M.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$4.23M
72.16% YoYΔ $-10.97M vs prior year quarter

Peer average

Loading

LAVA Therapeutics NV Total Current Liabilities History

Loading

LAVA Therapeutics NV vs. peers: Total Current Liabilities Comparison

Loading

LAVA Therapeutics NV Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

LAVA Therapeutics NV (LVTX) FAQ

The latest total current liabilities for LVTX is $4.2M as of September 2025. That compares with $15M in the prior-year period — down 72.2% year over year. Investors often review this figure alongside LAVA Therapeutics NV's historical trend and sector peers before judging valuation or financial health.

Over the past year, LVTX's total current liabilities moved from $15M to $4.2M — a 72.2% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in LAVA Therapeutics NV's operating scale or balance-sheet position.

A total current liabilities figure of $4.2M for LVTX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting LVTX's total current liabilities ($4.2M), review year-over-year change from $15M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack LAVA Therapeutics NV's total current liabilities against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.